
Edwards Lifesciences Corp ownership: holders and insider trading
$107.11−0.04%Close 16 Nov 2026 · Market value $61.54B
As filed, its directors and officers own 0.3% of the shares (proxy statement, 31 Jan 2026); 1,320 institutional managers reported holding 91.0% at 30 Jun 2026. Over the last twelve months, insiders sold $34.06M of shares on the open market, $20.87M of it under 10b5-1 plans set in advance, and bought none.
From the company's proxy statement, each holder's latest Schedule 13D or 13G, the institutional managers' quarterly 13F reports and the insiders' Form 4 filings. A percentage is shown as filed; one marked * is worked out here from the shares outstanding.
Largest holders
| Holder | Type | Shares | Of the company | Source | As of |
|---|
| The Vanguard Group | Holder | 70.0M | 12.16%* | Form 13F | 30 Jun 2026 |
|---|
| BlackRock, Inc. | Holder | 58.8M | 10.21%* | Form 13F | 30 Jun 2026 |
|---|
| Vanguard Capital Management | Holder | 43.5M | 7.54% | Schedule 13G | 31 Mar 2026 |
|---|
| State Street | Institution | 26.3M | 4.57%* | Form 13F | 30 Jun 2026 |
|---|
| JPMorgan Chase | Institution | 22.8M | 3.96%* | Form 13F | 30 Jun 2026 |
|---|
| Wellington Management | Institution | 16.8M | 2.92%* | Form 13F | 30 Jun 2026 |
|---|
| Geode Capital Management | Institution | 15.4M | 2.68%* | Form 13F | 30 Jun 2026 |
|---|
| BNY | Institution | 14.1M | 2.45%* | Form 13F | 30 Jun 2026 |
|---|
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | Institution | 13.0M | 2.26%* | Form 13F | 30 Jun 2026 |
|---|
| Ninety One UK Ltd | Institution | 12.3M | 2.14%* | Form 13F | 30 Jun 2026 |
|---|
| Aristotle Capital Management, LLC | Institution | 8.7M | 1.51%* | Form 13F | 30 Jun 2026 |
|---|
| Alliancebernstein L.p. | Institution | 8.7M | 1.50%* | Form 13F | 30 Jun 2026 |
|---|
| Fidelity (FMR) | Institution | 8.4M | 1.47%* | Form 13F | 30 Jun 2026 |
|---|
| Norges Bank | Institution | 8.4M | 1.45%* | Form 13F | 30 Jun 2026 |
|---|
| UBS | Institution | 7.8M | 1.36%* | Form 13F | 30 Jun 2026 |
|---|
| Brown Advisory Inc | Institution | 7.4M | 1.28%* | Form 13F | 30 Jun 2026 |
|---|
| Bank of America | Institution | 6.7M | 1.16%* | Form 13F | 30 Jun 2026 |
|---|
| Artisan Partners Limited Partnership | Institution | 6.6M | 1.15%* | Form 13F | 30 Jun 2026 |
|---|
| Morgan Stanley | Institution | 6.3M | 1.10%* | Form 13F | 30 Jun 2026 |
|---|
| Arrowstreet Capital, Limited Partnership | Institution | 5.7M | 0.99%* | Form 13F | 30 Jun 2026 |
|---|
Insider transactions latest 25
| Insider | Date | Transaction | Shares | Price | Value |
|---|
| Dahl Andrew M. · SVP, Corporate Controller | 13 Nov 2026 | Shares withheld for tax | −101 | $105.80 | $10.69K |
|---|
| Lippis Daniel J. · CVP, TAVR | 10 Nov 2026 | Option exercise | +619 | $72.68 | $44.99K |
|---|
| Lippis Daniel J. · CVP, TAVR | 10 Nov 2026 | Open-market sale (10b5-1 plan) | −619 | $104.25 | $64.53K |
|---|
| Zovighian Bernard J · CEO · Director | 9 Nov 2026 | Option exercise | +23.1K | $72.68 | $1.68M |
|---|
| Zovighian Bernard J · CEO · Director | 9 Nov 2026 | Open-market sale (10b5-1 plan) | −9.2K | $103.39 | $949.5K |
|---|
| Zovighian Bernard J · CEO · Director | 9 Nov 2026 | Open-market sale (10b5-1 plan) | −13.9K | $102.78 | $1.43M |
|---|
| BOBO DONALD E JR · CVP,Strategy/Corp Development | 9 Nov 2026 | Option exercise | +48.9K | $72.68 | $3.55M |
|---|
| BOBO DONALD E JR · CVP,Strategy/Corp Development | 9 Nov 2026 | Open-market sale (10b5-1 plan) | −48.9K | $103.05 | $5.04M |
|---|
| Lippis Daniel J. · CVP, TAVR | 8 Oct 2026 | Option exercise | +619 | $72.68 | $44.99K |
|---|
| Lippis Daniel J. · CVP, TAVR | 8 Oct 2026 | Open-market sale (10b5-1 plan) | −619 | $85.65 | $53.02K |
|---|
| Markowitz Wayne · CVP, JAPAC | 14 Sep 2026 | Shares withheld for tax | −568 | $84.37 | $47.92K |
|---|
| Dahl Andrew M. · SVP, Corporate Controller | 13 Sep 2026 | Shares withheld for tax | −253 | $84.37 | $21.35K |
|---|
| Markowitz Wayne · CVP, JAPAC | 11 Sep 2026 | Shares withheld for tax | −355 | $86.77 | $30.80K |
|---|
| Chopra Daveen · CVP, TMTT, Surgical & IHFM | 11 Sep 2026 | Shares withheld for tax | −398 | $86.77 | $34.53K |
|---|
| Lippis Daniel J. · CVP, TAVR | 11 Sep 2026 | Option exercise | +619 | $72.68 | $44.99K |
|---|
| Lippis Daniel J. · CVP, TAVR | 11 Sep 2026 | Open-market sale (10b5-1 plan) | −619 | $87.51 | $54.17K |
|---|
| Dahl Andrew M. · SVP, Corporate Controller | 31 Aug 2026 | Open-market sale | −544 | $91.06 | $49.54K |
|---|
| Bruls Annette · CVP, EMEACLA | 28 Aug 2026 | Open-market sale | −2.6K | $89.98 | $237.9K |
|---|
| Chopra Daveen · CVP, TMTT, Surgical & IHFM | 26 Aug 2026 | Option exercise | +31.8K | $72.68 | $2.31M |
|---|
| Chopra Daveen · CVP, TMTT, Surgical & IHFM | 26 Aug 2026 | Open-market sale | −30.6K | $90.99 | $2.79M |
|---|
| Chopra Daveen · CVP, TMTT, Surgical & IHFM | 26 Aug 2026 | Open-market sale | −1.2K | $91.76 | $105.9K |
|---|
| Markowitz Wayne · CVP, JAPAC | 26 Aug 2026 | Open-market sale | −1.2K | $91.47 | $113.4K |
|---|
| Lippis Daniel J. · CVP, TAVR | 11 Aug 2026 | Option exercise | +619 | $72.68 | $44.99K |
|---|
| Lippis Daniel J. · CVP, TAVR | 11 Aug 2026 | Open-market sale (10b5-1 plan) | −619 | $92.03 | $56.97K |
|---|
| Markowitz Wayne · CVP, JAPAC | 30 Jul 2026 | Open-market sale | −146 | $86.03 | $12.59K |
|---|
Form 4 filings since 17 Nov 2024: purchases and sales, grants, option exercises and shares withheld for tax. Gifts and other transfers are left out.
EW in the terminal
Holders over eight quarters by family, every Form 4 and Form 144 back two years, and alerts on insider buying.